Oppenheimer Weighs in on BioLineRx’s FY2021 Earnings (BLRX)

BioLineRx (NASDAQ:BLRX) – Research analysts at Oppenheimer increased their FY2021 earnings estimates for shares of BioLineRx in a report released on Tuesday, May 22nd. Oppenheimer analyst M. Breidenbach now anticipates that the biotechnology company will post earnings per share of $0.07 for the year, up from their previous forecast of $0.04. Oppenheimer also issued estimates for BioLineRx’s FY2022 earnings at $0.08 EPS.

BioLineRx (NASDAQ:BLRX) last issued its quarterly earnings data on Tuesday, May 22nd. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.01.

Other research analysts also recently issued research reports about the stock. Zacks Investment Research raised shares of BioLineRx from a “hold” rating to a “buy” rating and set a $1.00 target price for the company in a research report on Friday. HC Wainwright set a $4.00 target price on shares of BioLineRx and gave the company a “buy” rating in a research report on Tuesday. Finally, ValuEngine raised shares of BioLineRx from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. BioLineRx has a consensus rating of “Buy” and an average target price of $2.80.

Shares of BLRX stock opened at $0.91 on Thursday. BioLineRx has a 12-month low of $0.78 and a 12-month high of $1.34. The firm has a market cap of $97.80 million, a PE ratio of -3.37 and a beta of 0.53.

A hedge fund recently raised its stake in BioLineRx stock. Renaissance Technologies LLC raised its position in BioLineRx (NASDAQ:BLRX) by 60.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 434,700 shares of the biotechnology company’s stock after acquiring an additional 164,500 shares during the quarter. Renaissance Technologies LLC owned approximately 0.41% of BioLineRx worth $474,000 at the end of the most recent reporting period. 35.72% of the stock is owned by institutional investors.

BioLineRx Company Profile

BioLineRx Ltd., a clinical stage biopharmaceutical development company focused on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions.

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Contrasting ADVA Optical Networking  & Ability
Contrasting ADVA Optical Networking & Ability
Financial Comparison: Ituran Location and Control Ltd.   vs. TE Connectivity
Financial Comparison: Ituran Location and Control Ltd. vs. TE Connectivity
Zacks: Analysts Expect iRobot Co.  Will Announce Quarterly Sales of $221.22 Million
Zacks: Analysts Expect iRobot Co. Will Announce Quarterly Sales of $221.22 Million
bitCNY  Price Up 2.8% This Week
bitCNY Price Up 2.8% This Week
Signal Token Trading 136.8% Higher  This Week
Signal Token Trading 136.8% Higher This Week
Brokerages Expect Catabasis Pharmaceuticals Inc  Will Announce Earnings of -$0.27 Per Share
Brokerages Expect Catabasis Pharmaceuticals Inc Will Announce Earnings of -$0.27 Per Share


© 2006-2018 Ticker Report. Google+.